<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>554</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15223322</PubmedId>
            <Abstract>Antibodies targeting human epithelial carcinomas bearing Lewis Y (Le(y)) carbohydrate antigens provide a striking illustration of convergent immune recognition. We report a 1.9A resolution crystal structure of the Fab of a humanized antibody (hu3S193) in complex with the Le(y) tetrasaccharide, Fuc(alpha 1--&gt;2)Gal(beta 1--&gt;4)[Fuc(alpha 1--&gt;3)]GlcNAc. Comparisons of the hu3S193 and BR96 antibodies bound to Le(y) tumor antigens revealed extremely similar mechanisms for recognition of the carbohydrate epitopes. Solvent plays a critical role in hu3S193 antibody binding to the Le(y) carbohydrate epitope. Specificity for Le(y) is maintained because a conserved pocket accepts an N-acetyl group of the core Gal(beta 1--&gt;4)GlcNAc disaccharide. Closely related blood-group determinants (Le(a) and Le(b)) cannot enter the specificity pocket, making the Le(y) antibodies promising candidates for immunotherapy of epithelial cancer.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>809-18</ArticlePages>
            <ArticleTitle>Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Ramsland</LastName>
                    <ForeName>Paul A</ForeName>
                </Author>
                <Author>
                    <LastName>Farrugia</LastName>
                    <ForeName>William</ForeName>
                </Author>
                <Author>
                    <LastName>Bradford</LastName>
                    <ForeName>Tessa M</ForeName>
                </Author>
                <Author>
                    <LastName>Mark Hogarth</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Scott</LastName>
                    <ForeName>Andrew M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Structural Immunology Laboratory, Austin Research Institute, Heidelberg, Vic. 3084, Australia. p.ramsland@ari.unimelb.edu.au.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Neoplasm;Antigens, Tumor-Associated, Carbohydrate;Carbohydrates;Complementarity Determining Regions;Epitopes;Immunoglobulin Fab Fragments;Lewis Blood Group Antigens;Ligands;Oligosaccharides</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Amino Acid Substitution; Antibodies, Monoclonal(immunology); Antibodies, Neoplasm(immunology); Antibody Specificity; Antigens, Tumor-Associated, Carbohydrate(chemistry; immunology); Binding Sites, Antibody; Carbohydrate Conformation; Carbohydrate Sequence; Carbohydrates(immunology); Carcinoma(immunology); Complementarity Determining Regions; Crystallography, X-Ray; Epitopes; Humans; Immunoglobulin Fab Fragments(chemistry); Lewis Blood Group Antigens(chemistry; immunology); Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms, Glandular and Epithelial(immunology); Oligosaccharides(chemistry; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>340</Volume>
                <Issue>4</Issue>
                <Title>Journal of molecular biology</Title>
                <Issn>0022-2836</Issn>
                <MedlineTa>J Mol Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Lewis Y (Le&lt;sup&gt;y&lt;/sup&gt;) tetrasaccharide</EpitopeName>
                <EpitopeStructure>
                    <AccessionNonSequenceMolecule>
                        <ChemicalType>Carbohydrate</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:59045</ChEBIId>
                        </Molecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </AccessionNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Abstract</LocationOfData>
                <EpitopeId>130644</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 2, 3, 4, 5, 6 and 1S3K</LocationOfData>
                        <BCellId>1861908</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Human MCF-7 breast carcinoma</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <DoseSchedule>4 to 6 doses of 3 to 10 x 10&lt;sup&gt;6&lt;/sup&gt; MCF-7 breast carcinoma cell line</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent mouse monoclonal antibody 3S193 was previously described in the cited references: Kitamura et al. (1994) Proc Natl Acad Sci USA 91: 12957–12961[PMID: 7809154] and Scott et al. (2000) Cancer Res 60(12): 3254-361 [PMID: 10866319]. The hu3S193 antibody is a humanized version of the murine 3S193 monoclonal IgG3 antibody generated by immunization of BALB/c mice with human MCF-7 breast carcinoma cells, which were positive for the Lewis Y tumor antigen.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>1.9</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The crystal structure of the hu3S193 Fab–Lewis Y complex was determined by the molecular replacement method.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Antibody construct</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>hu3S193</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Hu3s193</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1S3K_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1S3K_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Carbohydrate</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:59045</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1S3K</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>H</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Details of contacts are not discussed in the paper.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>H: (FUC)223, (GAL)224, (NDG)225, (FUC)226</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>L: H31:L1, N33:L1, Y37:L1; H: Y32:H1, Y33:H1, Y35:H1, T100:H3, S104:H3, W105:H3</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>282.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>243.0</ContactAreaForAntibody>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>H: (FUC)223, (GAL)224, (NDG)225, (FUC)226</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: D31, Y32, Y33, Y35, T100, R101, G103, S104, W105; L: H31, N33, Y37</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>462.2</ContactAreaForAntigen>
                                <ContactAreaForAntibody>322.8</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

